All News
Updates in SLE and APS
2026 EULAR Press Release
Systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) often overlap. While there have been some therapeutic advances, significant needs remain around diagnosis and monitoring, with a gap around definitions and biomarkers for refractory disease or specific subsets.
Read Article
Can we finally personalize MTX dosing in #RA? liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay (n=59): MTX-PG3 levels ↑ with dose and age, ↓ with higher disease activity and concomitant biologics. Route (oral vs SC) didn't matter. @RheumNow #EULAR2026 POS0251
Jiha Lee JihaRheum ( View Tweet)
SPARTAN-SSR: New quantitative criteria: BME in ≥3 consecutive slices OR any two of (BME, Erosion, Fat lesion each in ≥3 SIJ quadrants) or ankylosis in ≥3 halves achieves 88-96% sensitivity and 90-98% specificity across 3 cohorts. Precision #axSpA imaging. Abstr OP0100
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#EULAR2026 POS0713 Is there a hope for BTK-inhibition in #SLE despite several previous failures? A Phase IIb RCT in China: primary endpoint (SRI-4) was met in Orelabrutinib vs PBO in dose-dependent manner. No new safety signal. Phase 3 RCT is underway @RheumNow https://t.co/4cJ8ezppTS
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Gecacitinib (pan-JAK inhibitor) vs placebo in radiographic #axSpA ASAS40 51.9% vs 12.9% (p<0.0001) at 16 weeks. ASAS20 69.2% vs 21.2% (p<0.0001). Pan-JAK inhibition showed efficacy in TNFi-experienced patients. Abstr OP0240 @RheumNow #EULAR2026
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#proof of #concept in #Sjogren’s #dis
#lanalumab Treatment reduced in #SjD
✅reduced B cells in #salivary #glands
—nearly complete depletion in serum
✅reduced B cell activation
✅improved #inflammation of
#parotid & #submandibular glands
@RheumNow #EULAR2026
#OP0163
#POS0284
Janet Pope Janetbirdope ( View Tweet)
Interim results from ASTER, a study on real world effectiveness of ANI in SLE: Pts receiving ANI had improvements in total SLEDAI-2K scores after 1 yr ffup period
MCT, MSK & hema had the highest decrease in SLEDAI-2K scores from pre-tx to 1yr ffup
OP342 @RheumNow #EULAR2026 https://t.co/DArOwQtxM6
Links:
sheila RHEUMarampa ( View Tweet)
ETA+MTX vs triple therapy after MTX failure in #RA: machine learning-emulated RACAT trial (n=3,472 VA pts) confirms ETA+MTX modestly better overall. But smoking matters: benefit disappears in current smokers. Precision medicine from RWD. @RheumNow #EULAR2026 POS0255
Jiha Lee JihaRheum ( View Tweet)
Baricitinib inhibits substance P and IL6 - by interfering with the pathway NGF-IL6-SP axis. This is a novel pathway to pain suppression in RA
#EULAR2026 #pos0217 @rheumnow https://t.co/6MsrFH3Mm0
Bella Mehta bella_mehta ( View Tweet)
#EULAR2026 POS0156 “TWO’S company, THREE’S a crowd” Tri-specific CD19/CD3/CD28 (i.e. CD28 co-stimulates Tcell activation) TriTE via IV showed early efficacy & safety in 11 #SLE patients up to 48WKS. Longer FU needed to see if repeat dosing needed @RheumNow https://t.co/FpXzJIYwZF
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Rapcabtagene Autoleucel -YTB323 rapidly manufactured CD19 CAR T
#POS0303 #EULAR2026 @RheumNow
24 months follow up data for 21 pts.
Durable b cell reduction and decrease in disease activity. https://t.co/m3lYjZJJIy
Links:
Bella Mehta bella_mehta ( View Tweet)
#OP0342 Interim real-world ASTER data showed anifrolumab improved overall SLEDAI-2K scores & reduced disease activity across multiple organ systems over 12 months, particularly mucocutaneous & MSK domains. Nearly 30% achieved SLEDAI-2K=0 at 1 year. #EULAR2026 @RheumNow https://t.co/IJlDnHSTh2
Mrinalini Dey DrMiniDey ( View Tweet)
Hypertension was the most robust and consistent predictor of pre term labor. Data from germany nationwide #POS1062 @RheumNow ##EULAR2026 https://t.co/Uccf11PpAK
Bella Mehta bella_mehta ( View Tweet)
#OP0336 Exploratory analyses from REGENCY👑 OBI +standard tx induced ⬆️ histological remission & markedly greater kidney tissue B-cell depletion vs PBO in lupus nephritis. Many patients without clinical CRR still achieved histologic remission. #EULAR2026 @RheumNow #EULARBest https://t.co/DoOlRO9QsC
Mrinalini Dey DrMiniDey ( View Tweet)
#OP0340 Long-term DARALUP data suggest CD38-targeting with daratumumab may be promising in refractory SLE, with rapid serologic and clinical improvements sustained to 84 weeks in many patients. Flares occurred in 6/10 patients but responded to belimumab. #EULAR2026 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
Post marketing safety signals of anifrolumab from US FDA adverse event reporting system - herpes zoster significantly associated.
Others include infusion reactions and intermittent hypersensitivity @RheumNow ##EULAR2026 #POS1067
Bella Mehta bella_mehta ( View Tweet)
Sarcoidosis increases the risk of MGUS and multiple myeloma. Propensity matched Data from a large global collaborative network study with 40k pts.
POS0231 #EULAR2026 @RheumNow https://t.co/mygYCjigFV
Bella Mehta bella_mehta ( View Tweet)
#EULAR2026 POS0683 Additional analysis of ALLEGORY RCT: in addition to meeting primary endpoint (SRI-4) and 5 key secondary endpoints, Obinutuzumab led to greater DORIS remission and LLDAS vs PBO in nonrenal #SLE. Under FDA review for license extension to non-renal @RheumNow https://t.co/HhZNX3w8v5
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Does sequential therapy infliximab —> tofacitinib outperform tofa alone in axSpA?
Yes: faster remission at week 4 (84.6% vs 15%)
But: equal at week 24
Prospective study in 46 patients
#POS0201 #EULAR2026 @RheumNow https://t.co/rmtoJQtYc0
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Top tips:
⭐️ Summarise the key facts but always provide the source
⭐️ Learn from mistakes to improve what you have
⭐️ Have high quality source material- scan multiple resources for the best quality info and latest news!
@RheumNow
#EULAR2026
Mrinalini Dey DrMiniDey ( View Tweet)
